Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyperthermia + Olaparib in Breast Cancer With Chest Wall Recurrences
NCT03955640Phase 1Terminated
- Sponsor
- Thomas Jefferson University
- Start
- May 2019
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of olaparib in breast cancer, sponsored by Thomas Jefferson University. Primary endpoint: Incidence of adverse events. Started May 2019; status: terminated.
02
Drugs
olaparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03955640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03955640.